| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 41.46% | Jefferies | → $29 | Initiates Coverage On | → Buy |
| 08/08/2023 | 41.46% | Guggenheim | → $29 | Initiates Coverage On | → Buy |
What is the target price for Apogee Therapeutics (APGE)?
The latest price target for Apogee Therapeutics (NASDAQ: APGE) was reported by Jefferies on August 8, 2023. The analyst firm set a price target for $29.00 expecting APGE to rise to within 12 months (a possible 41.46% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Apogee Therapeutics (APGE)?
The latest analyst rating for Apogee Therapeutics (NASDAQ: APGE) was provided by Jefferies, and Apogee Therapeutics initiated their buy rating.
When is the next analyst rating going to be posted or updated for Apogee Therapeutics (APGE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apogee Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apogee Therapeutics was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
Is the Analyst Rating Apogee Therapeutics (APGE) correct?
While ratings are subjective and will change, the latest Apogee Therapeutics (APGE) rating was a initiated with a price target of $0.00 to $29.00. The current price Apogee Therapeutics (APGE) is trading at is $20.50, which is within the analyst's predicted range.